ProKidney Corp.
PROK•NASDAQ•Healthcare•Biotechnology

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBruce Culleton
Founded2015
Employees204
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
Share ClassClass A Shares

Contact Information

Websiteprokidney.com
Phone336 999 7028
Address
2000 Frontis Plaza Blvd., Suite 250 Winston-Salem, North Carolina 27103 United States

Corporate Identifiers

CIK0001850270
CUSIP74291D104
ISINUS74291D1046
EIN98-1586514
SIC2836

Leadership Team & Key Executives

Dr. Bruce Culleton M.D.
Chief Executive Officer and Director
Dr. Ulrich Ernst Ph.D.
Executive Vice President of Science and Technology
Todd C. Girolamo Esq., J.D., M.B.A.
Chief Legal Officer and Secretary
James Coulston CPA
Chief Financial Officer
Anu Biswas
Senior Vice President of Manufacturing and Operations
Richard Williams
Chief Information Officer
Carla Poulson
Chief People Officer
Dr. Joseph M. Stavas M.D., M.P.H.
SVice President of Clinical Affairs
Dr. Darin J. Weber Ph.D.
Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access
Nikhil L. Pereira-Kamath
Chief Business Officer